Continued Research and Development
First written in FY2017-Q1. 24 of 31 entries say "Restated". Latest entry: FY2026.
45 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Total research and development expenses for the current consolidated fiscal year were ¥588.978 million.」
Total research and development expenses increased from ¥553.007 million in the previous fiscal year to ¥588.978 million. Research and development continued on BankNeo, GAKUEN, medical big data, and other areas. - 2026-05-14AdvancedRevision of earnings forecasts
「For our proprietary-brand products, including the strategic university management system “GAKUEN” series, the integrated information system “BankNeo” for financial institutions, and the automated medical claims-review system “JMICS,” we will strengthen our competitive advantages through R&D investment and the use of generative AI. We will also expand our service lines by leveraging our customer base to increase market share and customer lifetime value (LTV).」
Specific R&D measures were presented, including investment in existing branded products and the use of generative AI. - FY2026-H1Research and development expenses increased, but there were no significant changes in activities.Annual report
「Research and development expenses for the current interim consolidated fiscal period were ¥177 million. There were no significant changes in research and development activities during the period.」
The Company continued to explain that there were no significant changes in research and development activities, while research and development expenses increased from ¥137 million in the same period of the previous year to ¥177 million. - FY2025AdvancedAnnual report
「Total research and development expenses for the current consolidated fiscal year were ¥553.007 million. In the Package Business, the Company worked to enhance the functionality of BankNeo, an integrated information system for financial institutions, and to develop new functions for the GAKUEN series of strategic university management systems, resulting in research and development expenses of ¥276.317 million.」
Total research and development expenses increased to ¥553.007 million from ¥469 million in the previous fiscal year. Research and development continued on enhancements to BankNeo, new GAKUEN functions, and medical big data. - FY2024-Q3RestatedAnnual report
「Research and development expenses for the cumulative third quarter of the current consolidated fiscal year were ¥224 million. There were no significant changes in research and development activities during the period.」
Cumulative research and development expenses for the third quarter were ¥224 million, while the Company continued to explain that there were no significant changes in research and development activities. - FY2024-Q2Research and development expenses declined, but there were no significant changes in activities.Annual report
「Research and development expenses for the cumulative second quarter of the current consolidated fiscal year were ¥120 million. There were no significant changes in research and development activities during the period.」
The Company continued to explain that there were no significant changes in research and development activities, while research and development expenses decreased from ¥199 million in the same period of the previous year to ¥120 million. - FY2024-Q1RestatedAnnual report
「Research and development expenses for the cumulative first quarter of the current consolidated fiscal year were ¥40 million. There were no significant changes in research and development activities during the period.」
The Company continues to explain that there were no significant changes in research and development activities. Cumulative research and development expenses for the first quarter were ¥40 million. - FY2023AdvancedAnnual report
「Total research and development expenses for the current consolidated fiscal year were ¥469 million.」
Total research and development expenses increased to ¥469 million from ¥436 million in the previous fiscal year. Research and development continued in DX & SI, package products, medical big data, and areas outside specific businesses. - FY2023-Q3RestatedAnnual report
「Research and development expenses for the cumulative third quarter of the current consolidated fiscal year were ¥329 million. There were no significant changes in research and development activities during the period.」
The Company continues to explain that there were no significant changes in research and development activities. Cumulative research and development expenses for the third quarter were ¥329 million. - FY2023-Q2RestatedAnnual report
「Research and development expenses for the cumulative second quarter of the current consolidated fiscal year were ¥199 million. There were no significant changes in research and development activities during the period.」
The Company continues to explain that there were no significant changes in research and development activities. Cumulative research and development expenses for the second quarter were ¥199 million. - FY2023-Q1RestatedAnnual report
「Research and development expenses for the cumulative first quarter of the current consolidated fiscal year were ¥74 million. There were no significant changes in research and development activities during the period.」
The Company continues to explain that there were no significant changes in research and development activities. Cumulative research and development expenses for the first quarter were ¥74 million. - FY2022RestatedAnnual report
「Total research and development expenses for the current consolidated fiscal year were ¥436 million. Research and development activities by segment are as follows.」
Research and development activities continued, and total research and development expenses were ¥436 million. The Software Business worked on new businesses and next-generation products for financial institutions, the GAKUEN Business worked on new products, and the Medical Big Data Business worked to improve inspection performance and expand services. - FY2022-Q3RestatedAnnual report
「Research and development expenses for the cumulative third quarter of the current consolidated fiscal year were ¥264 million. There were no significant changes in research and development activities during the period.」
The Company continues to explain that there were no significant changes in research and development activities. Cumulative research and development expenses for the third quarter were ¥264 million. - FY2021RestatedAnnual report
「Total research and development expenses for the current consolidated fiscal year were ¥399 million. In the Software Business, the Company conducted research aimed at creating new businesses and worked on developing next-generation products for financial institutions, resulting in research and development expenses of ¥150 million.」
Research and development activities continued, including work on new businesses, next-generation products for financial institutions, new GAKUEN products, and medical big data. Total research and development expenses were ¥399 million. - FY2021-Q3RestatedAnnual report
「Research and development expenses for the cumulative third quarter of the current consolidated fiscal year were ¥315 million. There were no significant changes in research and development activities during the period.」
The Company continues to explain that there were no significant changes in research and development activities. Cumulative research and development expenses were ¥315 million. - FY2021-Q2RestatedAnnual report
「Research and development expenses for the cumulative second quarter of the current consolidated fiscal year were ¥195 million. There were no significant changes in research and development activities during the period.」
The Company continues to explain that there were no significant changes in research and development activities. Research and development expenses were ¥195 million. - FY2021-Q1RestatedAnnual report
「Research and development expenses for the cumulative first quarter of the current consolidated fiscal year were ¥70 million. There were no significant changes in research and development activities during the period.」
The Company continues to explain that there were no significant changes in research and development activities. Research and development expenses were ¥70 million. - FY2020RestatedAnnual report
「Total research and development expenses for the current consolidated fiscal year were ¥442 million. Research and development activities by segment are as follows.」
Research and development activities continued, and total research and development expenses were ¥442 million. The report describes research and development related to new GAKUEN products, next-generation products for financial institutions, and medical big data. - FY2020-Q2RestatedAnnual report
「Research and development expenses for the cumulative second quarter of the current consolidated fiscal year were ¥173 million. There were no significant changes in research and development activities during the period.」
The Company continues to explain that there were no significant changes in research and development activities. Research and development expenses were ¥173 million. - FY2020-Q1RestatedAnnual report
「Research and development expenses for the cumulative first quarter of the current consolidated fiscal year were ¥81 million. There were no significant changes in research and development activities during the period.」
The Company continues to explain that there were no significant changes in research and development activities. Research and development expenses were ¥81 million. - FY2019RestatedAnnual report
「Total research and development expenses for the current consolidated fiscal year were ¥492 million.」
Research and development activities continued, and total research and development expenses were ¥492 million. The report describes research and development related to next-generation products for financial institutions, new GAKUEN products, and medical big data. - FY2019-Q3RestatedAnnual report
「Research and development expenses for the cumulative third quarter of the current consolidated fiscal year were ¥349 million. There were no significant changes in research and development activities during the period.」
The Company continues to explain that there were no significant changes in research and development activities. Research and development expenses were ¥349 million. - FY2019-Q2RestatedAnnual report
「Research and development expenses for the cumulative second quarter of the current consolidated fiscal year were ¥231 million. There were no significant changes in research and development activities during the period.」
The Company continues to explain that there were no significant changes in research and development activities. Research and development expenses were ¥231 million. - FY2019-Q1RestatedAnnual report
「Research and development expenses for the cumulative first quarter of the current consolidated fiscal year were ¥91 million. There were no significant changes in research and development activities during the period.」
The Company continues to explain that there were no significant changes in research and development activities. Research and development expenses were ¥91 million. - FY2018-Q3RestatedAnnual report
「Research and development expenses for the cumulative third quarter of the current consolidated fiscal year were ¥309 million. There were no significant changes in research and development activities during the period.」
The Company continues to explain that there were no significant changes in research and development activities. Research and development expenses were ¥309 million. - FY2018-Q2RestatedAnnual report
「Research and development expenses for the cumulative second quarter of the current consolidated fiscal year were ¥196 million. There were no significant changes in research and development activities during the period.」
The Company continues to explain that there were no significant changes in research and development activities. Research and development expenses were ¥196 million. - FY2018-Q1RestatedAnnual report
「Research and development expenses for the cumulative first quarter of the current consolidated fiscal year were ¥89 million. There were no significant changes in research and development activities during the period.」
The Company continues to explain that there were no significant changes in research and development activities. Research and development expenses were ¥89 million. - FY2017RestatedAnnual report
「In the Package Business, the Company worked on developing a new integrated business package for universities, resulting in research and development expenses of ¥286 million. In the Medical Big Data Business, the Company focused on improving automated claims inspection performance and expanding services, resulting in research and development expenses of ¥45 million.」
Research and development activities continued, including development of new package products and improvements in inspection performance and expansion of services related to medical big data. Total research and development expenses were ¥332 million. - FY2017-Q3RestatedAnnual report
「Research and development expenses for the cumulative third quarter of the current consolidated fiscal year were ¥202 million. There were no significant changes in research and development activities during the period.」
The Company continues to explain that there were no significant changes in research and development activities. Research and development expenses were ¥202 million. - FY2017-Q2RestatedAnnual report
「Research and development expenses for the cumulative second quarter of the current consolidated fiscal year were ¥143 million. There were no significant changes in research and development activities during the period.」
The Company continues to explain that there were no significant changes in research and development activities. Research and development expenses were ¥143.51 million. - FY2017-Q1First statedAnnual report
「Research and development expenses for the cumulative first quarter of the current consolidated fiscal year were ¥66 million. There were no significant changes in research and development activities during the period.」
The Company continues to state that there were no significant changes in research and development activities during the quarter. Research and development expenses were ¥66 million.